Search results for "Nutrition disorders"
showing 3 items of 23 documents
Oral manifestations of eating disorders: a critical review.
2008
Background: Eating disorders (ED) are a group of psychopathological disorders affecting patient relationship with food and her/his own body, which manifests through distorted or chaotic eating behavior; they include anorexia nervosa, bulimia nervosa and ED not otherwise specified and may be burdened with life-threatening complications. As oral manifestations of ED can occur in many phases of disease progression, they play a significant role in assessment, characterization and prognosis of ED. Methods: Mucosal, dental, and salivary abnormalities associated with ED have been reviewed. Relations between oral menifestations and pathogenesis, management and prognosis of ED have been critically…
Breakdown of choline-containing phospholipids in rat brain during severe weight loss.
2002
Recent investigations in human anorectic patients indicated changes of brain choline metabolism. We used starved rats to investigate possible changes of brain choline metabolites during severe weight loss. Reductions of body weight by 15, 30 and 45% resulted in significant decreases of cerebral phosphatidylcholine and sphingomyelin levels. Concomitantly, the brain tissue content of glycerophosphocholine was increased while phosphocholine and free choline were unchanged. We conclude that severe weight loss is accompanied by phospholipase activation and breakdown of choline-containing phospholipids in the brain.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled…
2013
Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences o…